Comments
Here are the answers to readers’ queries on the performance of their stock holdings.
I brought Canara Bank shares at ₹217. Should I sell or hold?
KBD Prasaad
Canara Bank (₹96.1): The stock of Canara Bank has been in a long-term downtrend since recording a new high at ₹820 in late 2010. Both the medium- as well as the short-term trend is down for the stock. In early March, it decisively breached a key long-term support at around ₹150 and continued to trend downwards. After registering a multi-year low at ₹83 in the week before, the stock started to move sideways.
The daily relative strength index (RSI) is showing positive divergence, indicating possible trend-reversal in the short term. A strong rally above the immediate resistance level of ₹110 can take the stock higher to ₹127 and then to ₹140. Only a decisive rally above ₹150 will alter the short-term downtrend and take the stock higher to ₹170 and then to ₹185. The next vital resistance is at ₹200.
On the downside, a fall below the immediate support level of ₹90 can pull the stock down to ₹83 and then to ₹75.
The next supports are at ₹70 and ₹63. You can consider averaging the stock in declines with a stop-loss at ₹80. Consider booking profits if the stock struggles to move beyond ₹150 levels.
What are the prospects of Lupin and Aurobindo Pharma?
Pradeep Kabra
Lupin (₹641.6): The stock of Lupin is in a downtrend across all time-frames — long, medium and short term. After recording a multi-year low at ₹505 on March 13, the stock formed a hammer candlestick pattern in the daily chart, which is a bullish reversal pattern. It has been trending upwards since then.
There has been an increase in daily volume over the past two weeks. But the stock now tests resistance at ₹650. A strong break above this level will pave the way for an up-move to ₹₹685 and ₹700. A decisive rally above ₹720 will alter the downtrend and push the stock northwards to ₹750 and then to ₹775 levels.
The next key barrier is at ₹800. However, a fall below the immediate support level of ₹600 can pull the stock down to ₹575 and ₹505 levels.
Aurobindo Pharma (₹347): After a corrective medium-term uptrend, the stock of Aurobindo Pharma encountered resistance between ₹600 and ₹620 in late February, and resumed the long-term downtrend. Since then, the stock has been in a short-term downtrend. Currently, it tests a key support at ₹340. A fall below this level can pull the stock down to ₹300 and then to ₹260 over the medium term.
Conversely, a strong break above ₹400 can take the stock northwards to ₹450 and then to ₹500 in the same time frame.
Send your queries to techtrail@thehindu.co.in
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.